GOTHENBURG, SE / ACCESS Newswire / / AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that CEO Kristina Torfgård will present ...
Neurologist Andrew Wilner interviews headache expert Eric Baron about thunderclap headache and why a thorough workup is ...
She had just diagnosed our 11-year-old daughter, Maya, with Nicolaides-Baraitser syndrome, a genetic condition so rare there ...
A University of Cincinnati study links weekly physical activity to slower cognitive decline and motor function loss in Parkinson's disease patients.
A coma can look like deep sleep from the outside, but the brain is in a very different state. A person in coma cannot be ...
Alzinova is at an important stage of development. The global Phase II study of ALZ-101 is in operational start-up together with Worldwide Clinical Trials, with the aim of enrollin ...
First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability.Pixclara is the ...
Since October 1, Molina has been administering the Florida Children's CMS Plan instead of Sunshine. What happens with ...
Chicago-based healthcare software firm expands virtual care solutions with seamless Epic, Oracle Health, athenahealth, ...
5d
Stanford: Stanford Professor Wins Nobel Prize For Breakthrough In Controlling Nerve Cells With Light
A Stanford University professor was awarded the 2026 Nobel Prize in Physiology or Medicine for pioneering work that helped give scientists an unprecedented way to control and study nerve cells ...
Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, ...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results